Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Iron acquisition is critical for life. Ferroportin (FPN) exports iron from mature erythrocytes, and deletion of the Fpn gene results in hemolytic anemia and increased fatality in malaria-infected mice. The FPN Q248H mutation (glutamine to histidine at position 248) renders FPN partially resistant to hepcidin-induced degradation and was associated with protection from malaria in human studies of limited size. Using data from cohorts including over 18,000 African children, we show that the Q248H mutation is associated with modest protection against anemia, hemolysis, and iron deficiency, but we found little evidence of protection against severe malaria or bacteremia. We additionally observed no excess Plasmodium growth in Q248H erythrocytes ex vivo, nor evidence of selection driven by malaria exposure, suggesting that the Q248H mutation does not protect from malaria and is unlikely to deprive malaria parasites of iron essential for their growth.

Original publication

DOI

10.1126/sciadv.aaw0109

Type

Journal

Science advances

Publication Date

09/2019

Volume

5

Addresses

Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme, Kilifi, Kenya.

Keywords

Erythrocytes, Humans, Bacteremia, Malaria, Anemia, Iron, Cation Transport Proteins, Amino Acid Substitution, Mutation, Missense, Infant, Infant, Newborn, Female, Male, Iron Deficiencies